Novartis announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) has unanimously voted in support of the approval of AIN457 (secukinumab) for the treatment of moderate to severe plaque psoriasis.
New findings from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) indicate significantly better persistency and lower rates of discontinuation therapy with Stelara (ustekinumab; Jannsen Biotech) compared with anti-tumor necrosis factor (TNF)-alpha treatments.
Amgen announced that its Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared to Humira (adalimumab) in patients with moderate-to-severe plaque psoriasis met its primary endpoint.
Medac Pharma announced the launch of Rasuvo (methotrexate) injection for patients with rheumatoid arthritis, polyarticular course juvenile idiopathic arthritis (pJIA), and psoriasis.
AbbVie announced that the Food and Drug Administration (FDA) has approved the use of Humira (adalimumab) for moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) to reducing signs and symptoms in patients aged ≥2 years.
Ranbaxy announced the launch of Absorica (isotretinoin) 25mg and 35mg capsules for the treatment of severe recalcitrant nodular acne in patients ≥12 years old.
LEO Pharma announced that Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension has been approved for the treatment of plaque psoriasis of the scalp in patients aged 12-17 years.
AbbVie announced that the Food and Drug Administration (FDA) has approved Humira (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease for patients ≥6 years old.
Celgene announced that the Food and Drug Administration (FDA) has approved Otezla (apremilast) for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
AbbVie announced results from the Phase 3 PIONEER 1 study with Humira (adalimumab) in patients with moderate-to-severe hidradenitis suppurativa (HS).
The Food and Drug Administration (FDA) has granted accelerated approval for Keytruda (pembrolizumab; Merck) for the treatment of advanced or unresectable melanoma in patients who are no longer responsive to other drugs.
Eli Lilly and Company announced results from its Phase 3 UNCOVER studies of ixekizumab for the treatment of moderate-to-severe plaque psoriasis, in which ixekizumab was found to be superior to etanercept.
Auxilium announced positive results from a Phase 2a study of Xiaflex (collagenase clostridium histolyticum [CCH]) for the treatment of edematous fibrosclerotic panniculopathy (EEP), also known as cellulite.
Baxter announced that the FDA has approved Flexbumin (albumin [human]) 5% solution for the treatment of hypovolemia, hypoalbuminemia due to general causes, burns, and for use during cardiopulmonary bypass surgery as a component of the pump prime.
CareFusion announced the launch of its ChloraPrep 1mL applicator, the latest addition to the ChloraPrep line.
The FDA has approved the New Drug Application (NDA) for Acticlate (doxycycline hyclate) for the treatment of susceptible infections including adjunctive therapy in severe acne.
Medac Pharma announced that the FDA has approved Rasuvo (methotrexate) subcutaneous auto-injector for the management of rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis (pJIA), and severe, recalcitrant, disabling psoriasis.
Novartis announced results from two Phase 3 trials evaluating secukinumab in patients with moderate-to-severe plaque psoriasis.
PuraCap announced the introduction of EpiCeram Airless Pump, the latest addition to the EpiCeram line.
Aqua Pharmaceuticals announced the launch of Cordran Ointment (flurandrenolide) 0.05% for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
The FDA has issued a warning that certain over-the-counter (OTC) topical acne medications may cause rare but serious and potentially life-threatening allergic reactions or severe irritation.
Quest Products announced the launch of ProVent Eczema and Psoriasis Spray indicated to help minimize the appearance of skin conditions often associated with eczema and psoriasis.
Bristol-Myers Squibb's Phase 3 study, CheckMate -066 evaluating nivolumab vs. dacarbazine (DTIC) in patients with previously untreated BRAF wild-type advanced melanoma was stopped early due to an analysis demonstrating evidence of superior overall survival in patients receiving nivolumab compared to the control arm.
Valeant announced that the FDA has issued clearance for Restylane Silk Injectable Gel with 0.3% Lidocaine, a submucosal implant for lip augmentation and dermal implantation for correction of perioral rhytids in patients >21 years old.
Quest Products announced the launch of ProVent Rosacea Moisturizing Creme indicated to help reduce the appearance of skin often associated with rosacea and other skin conditions.
The FDA announced a final order reclassifying sunlamp products and ultraviolet (UV) lamps designed for use in sunlamp products from low-risk (Class I) to moderate-risk (Class II) devices.
Pfizer announced results from the OPT (Oral treatment Psoriasis Trial) Retreatment study (A3921111) assessing tofacitinib for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
Over $11.1 million worth of unapproved drugs have been seized by the U.S. marshals per request of the FDA and the U.S. Attorney for the Southern District of Ohio.
Mean adjusted annual health care costs associated with newly diagnosed psoriasis exceeds $4,000.
Pfizer announced top-line results from two pivotal Phase 3 trials, evaluating the efficacy and safety of Xeljanz (tofacitinib) for the treatment of moderate-to-severe plaque psoriasis.
Antares Pharma announced the publication of results from its crossover study comparing the relative bioavailability, safety, and tolerability of Otrexup (methotrexate) to oral methotrexate (MTX) in adults with rheumatoid arthritis in the Annals of the Rheumatic Diseases.
Understanding the treatment options and related side effects of UV therapy can guide the right therapeutic choice for patients with psoriasis.
Quest Products has announced that it will now distribute Alocane Emergency Burn Gel (Lidocaine HCl 4%), a topical gel for pain and itch relief.
Valeant announced that Luzu (luliconazole) Cream is now available.
Research on a technique for detecting the earliest spread of melanoma has confirmed that the procedure significantly prolongs patients' survival rates compared with traditional watch-and-wait techniques.
Merz Pharmaceuticals announced the launch of Mederma PM Intensive Overnight Scar Cream (dimethicone 2%), a new cream designed to work at night.
Janssen R&D announced results from X-PLORE, a Phase 2b study of guselkumab (CNTO 1959) in patients with moderate to severe plaque psoriasis.
Celgene announced the release of new research findings on Otezla (apremilast), a selective inhibitor of phosphodiesterase 4 (PDE4), from the ESTEEM 1 and 2 Phase 3 studies in patients with moderate to severe plaque psoriasis.
Pfizer announced results from OPT Compare (A3921080), a Phase 3 study of Xeljanz (tofacitinib) for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
Galderma announced results from two Phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of papulopusular rosacea.
Pierre Fabre Dermatologie has received FDA marketing approval of Hemangeol (propranolol HCl) oral solution for the treatment of proliferating infantile hemangioma requiring systemic therapy.
Amgen announced results from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene reduced the size of injected tumors and non-injected metastasized tumors.
Widespread use of pyrethrins- or pyrethroid-based products appears to have resulted in selection pressure for a highly-resistant strain of human head lice in North America.
For patients with advanced melanoma, nivolumab may improve overall survival and has an acceptable long-term safety profile.
Indoor tanning is common among high school students and is linked to engaging in other risky behaviors.
Excessive tanning may indicate the presence of psychiatric distress.
Adjuvant high-dose vitamin D3 is beneficial for patients with chronic urticaria.
Onset Dermatologics announced the launch of Minocin (minocycline HCl) 75mg pellet-filled capsules, a new dosage strength for Minocin.
Older men are more likely to have a whole-body skin exam done by their physician if they watch a video on skin self-examination and skin awareness.
Teledermatology is reliable for initial triage of patients, according to a study published online.
Onset Dermatologics announced the availability of Tretin-X (tretinoin) Cream 0.075%. Tretin-X Cream is indicated for the topical treatment of acne vulgaris.
FDA has approved Retin-A Micro (tretinoin; Valeant) gel microsphere 0.08%, a new strength of Retin-A Micro gel.
Agent Orange (2,3,7,8-tetrachlorodibenzodioxin) exposure is associated with increased incidence of nonmelanotic invasive skin cancer.
Galderma has announced that in a one-year, open-label, non-comparative study, Mirvaso (brimonidine) topical gel was demonstrated to be safe and effective when used once daily for up to 12 months.
Botanical extracts may be helpful in the treatment of hyperpigmentation, although identification of hyperpigmentation subtype may be important for treatment prognosis.
Scientists might be able to offer "hair-challenged" males a new glimmer of hope when it comes to reversing baldness.
Medac Pharma announced that the FDA has accepted for review its New Drug Application (NDA) for its lead product candidate MPI-2505 (methotrexate).
Lasers may be a promising treatment for onychomycosis but larger studies are needed to determine optimal treatment conditions.
Men with higher levels of melatonin may have a lower risk of developing prostate cancer.
Antares Pharma announced the availability of Otrexup (methotrexate for subcutaneous injection) for once-weekly self-administration with a single-dose disposable auto-injector.
Patients with systemic sclerosis have elevated levels of CXCL4, which predicts disease risk and progression.
A single facial fractional radiofrequency microneedle (FRM) treatment temporarily reduces sebum secretion and reduces acne severity.
A higher incidence of new primary melanomas was observed in patients with Stage III/IV melanoma who were male or who had a history of multiple primary melanomas.
Laser therapy is safe and effective for hypertrophic scar management.
The top five dermatology-related issues that physicians and patients should question have been released by the American Academy of Dermatology (AAD) as part of the Choosing Wisely campaign.
BTG plc announced that the FDA has approved Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system.
Young adult men who are unemployed for long periods have shorter telomeres, a sign of accelerated biological aging.
Three-dimensional (3D) high precision surface imaging can be used to monitor changes in the area and volume of port wine stains following laser treatment.
Amgen announced interim overall survival (OS) results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Valeant announced that the New Drug Application for Luzu (luliconazole) Cream, 1% has been approved by the FDA.
The FDA is requesting label and packaging changes to improve the safety of certain over-the-counter (OTC) topical antiseptic products.
Visual evidence in identical twins shows that smoking hastens facial aging, particularly in the middle and lower thirds of the face.
Monitoring changes in a biomarker can predict whether a class of melanomas will be sensitive to a particular class of drugs.
Fractional CO2 laser treatment is safe and seems effective for atrophic acne scars.
Moderate or severe psoriasis is associated with chronic kidney disease.
Good cosmetic outcomes are possible using fractionated ablative carbon dioxide laser therapy for mild-to-moderate cases of rhinophyma.
Antares Pharma announced that the FDA has approved Otrexup injection, the first SC methotrexate for once-weekly self-administration with an easy-to-use, single-dose, disposable auto-injector.
Patients with cutaneous malignant melanoma (CMM) may actually increase their exposure to ultraviolet radiation in the first three years after diagnosis.
There is a slight increased risk of rosacea among females with migraines.
Phototherapy with ultraviolet (UV) A1 radiation induces a reduction in serum 25-hydroxyvitamin D3 (25[OH]D) levels, whereas narrowband UVB (UVBnb) and UVA/UVBnb induces significant increases in serum 25(OH)D.
Low-level laser therapy (LLLT) seems to be effective and safe for hair growth in men and women.
The effects of appearance-enhancing procedures such as neuromodulators, fillers, and light or laser treatments have lasting effects and can rarely be used "too early".
Botox Cosmetic has been approved for an additional indication to temporarily treat moderate-to-severe crow's feet lines.
Physicians very rarely educate patients regarding the use of sunscreen and sun-protective behaviors.
MNK-795 (Mallinckrodt) achieved the primary endpoint in a Phase 3 efficacy trial for the treatment of moderate to severe acute pain following bunionectomy.
The FDA has approved Galderma's Mirvaso (brimonidine) topical gel for the topical treatment of the facial erythema associated with rosacea in adults 18 years or older.
Vitamin D may influence atopic dermatitis, and supplementation is associated with reduced disease severity.
The FDA has approved marketing of bioMerieux Inc.'s VITEK MS, the first mass spectrometer system for automated identification of 193 different microorganisms known to cause serious illness in humans.
For premenopausal women, sleep quality is associated with skin function and aging.
Nontreatment and undertreatment of psoriasis and psoriatic arthritis, including severe disease, is widespread in the United States.
For patients with psoriasis, major medical comorbidity increases with increasing severity of disease.
Several subgroups of patients with cutaneous lupus erythematosus (CLE) are deficient in their use of photoprotection
Merz announced that the FDA has approved Naftin Gel 2% for the treatment of interdigital-type tinea pedis.
Delayed primary skin closure may reduce the risk of infection after surgery, but the current studies are not definitive due to poor design.
Warner Chilcott announced the availability of a new 200mg dosage strength for Doryx (doxycycline hyclate) delayed-release tablets.
Exposure to antibiotics in the first year of life is associated with an increased likelihood of eczema, with increasing risk seen for each additional course of antibiotics.
ConvaTec has launched Aquacel Ag Foam dressing, the latest addition to the Aquacel family of wound management products.
Daily sunscreen use can slow skin aging in middle-aged adults.
Overweight patients with psoriasis have reduced disease severity and improved skin-related quality of life after weight loss.
Comorbid conditions often accompany alopecia areata.